291 related articles for article (PubMed ID: 25712313)
1. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.
Ly NS; Bulitta JB; Rao GG; Landersdorfer CB; Holden PN; Forrest A; Bergen PJ; Nation RL; Li J; Tsuji BT
J Antimicrob Chemother; 2015 May; 70(5):1434-42. PubMed ID: 25712313
[TBL] [Abstract][Full Text] [Related]
2. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
[TBL] [Abstract][Full Text] [Related]
3. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Jacob J; Sidjabat HE; Paterson DL; Nation RL; Li J
Antimicrob Agents Chemother; 2011 Dec; 55(12):5685-95. PubMed ID: 21911563
[TBL] [Abstract][Full Text] [Related]
4. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.
Rao GG; Ly NS; Bulitta JB; Soon RL; San Roman MD; Holden PN; Landersdorfer CB; Nation RL; Li J; Forrest A; Tsuji BT
J Antimicrob Chemother; 2016 Nov; 71(11):3148-3156. PubMed ID: 27494922
[TBL] [Abstract][Full Text] [Related]
5. Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa.
Ly NS; Bulman ZP; Bulitta JB; Baron C; Rao GG; Holden PN; Li J; Sutton MD; Tsuji BT
Antimicrob Agents Chemother; 2016 May; 60(5):2870-80. PubMed ID: 26926641
[TBL] [Abstract][Full Text] [Related]
6. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.
Deris ZZ; Yu HH; Davis K; Soon RL; Jacob J; Ku CK; Poudyal A; Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Paterson DL; Velkov T; Li J; Nation RL
Antimicrob Agents Chemother; 2012 Oct; 56(10):5103-12. PubMed ID: 22802247
[TBL] [Abstract][Full Text] [Related]
7. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
[TBL] [Abstract][Full Text] [Related]
8. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.
Yadav R; Bulitta JB; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821448
[TBL] [Abstract][Full Text] [Related]
9. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.
Mohamed AF; Cars O; Friberg LE
J Antimicrob Chemother; 2014 May; 69(5):1350-61. PubMed ID: 24474432
[TBL] [Abstract][Full Text] [Related]
10. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.
Bergen PJ; Forrest A; Bulitta JB; Tsuji BT; Sidjabat HE; Paterson DL; Li J; Nation RL
Antimicrob Agents Chemother; 2011 Nov; 55(11):5134-42. PubMed ID: 21876058
[TBL] [Abstract][Full Text] [Related]
11. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
Yadav R; Rogers KE; Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463528
[TBL] [Abstract][Full Text] [Related]
12. In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates.
Nazli E; Zer Y; Eksi F
J Int Med Res; 2015 Apr; 43(2):217-25. PubMed ID: 25547417
[TBL] [Abstract][Full Text] [Related]
13. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.
Mohamed AF; Kristoffersson AN; Karvanen M; Nielsen EI; Cars O; Friberg LE
J Antimicrob Chemother; 2016 May; 71(5):1279-90. PubMed ID: 26850719
[TBL] [Abstract][Full Text] [Related]
14. Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.
Yadav R; Bulitta JB; Schneider EK; Shin BS; Velkov T; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893782
[TBL] [Abstract][Full Text] [Related]
15. CSA-131, a ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates.
Vila-Farrés X; Callarisa AE; Gu X; Savage PB; Giralt E; Vila J
Int J Antimicrob Agents; 2015 Nov; 46(5):568-71. PubMed ID: 26395218
[TBL] [Abstract][Full Text] [Related]
16. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Bergen PJ; Li J; Nation RL; Turnidge JD; Coulthard K; Milne RW
J Antimicrob Chemother; 2008 Mar; 61(3):636-42. PubMed ID: 18227094
[TBL] [Abstract][Full Text] [Related]
17. Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.
Yadav R; Landersdorfer CB; Nation RL; Boyce JD; Bulitta JB
Antimicrob Agents Chemother; 2015 Apr; 59(4):2286-98. PubMed ID: 25645842
[TBL] [Abstract][Full Text] [Related]
18. In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
Gómez-Junyent J; Murillo O; Yu HH; Azad MAK; Wickremasinghe H; Rigo-Bonnin R; Benavent E; Ariza J; Li J
Int J Antimicrob Agents; 2021 Feb; 57(2):106246. PubMed ID: 33253904
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.
Bulitta JB; Yang JC; Yohonn L; Ly NS; Brown SV; D'Hondt RE; Jusko WJ; Forrest A; Tsuji BT
Antimicrob Agents Chemother; 2010 May; 54(5):2051-62. PubMed ID: 20211900
[TBL] [Abstract][Full Text] [Related]
20. Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.
Cheah SE; Li J; Nation RL; Bulitta JB
Antimicrob Agents Chemother; 2015 Jan; 59(1):381-8. PubMed ID: 25367905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
